Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Secreted frizzled-related protein 2 (SFRP2) gene methylation in blood shows promise as a prognostic biomarker for colorectal cancer (CRC) staging, invasion, and recurrence. SFRP2 also presents potential as a therapeutic target in CRC treatment.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Colorectal cancer (CRC) diagnosis and prognosis can be improved by identifying reliable biomarkers.
- Secreted frizzled-related protein 2 (SFRP2) has been suggested as a potential biomarker, but its diagnostic utility requires further investigation.
Purpose Of The Study
- To investigate the significance of SFRP2 gene methylation levels in various biological specimens from CRC patients.
- To assess the potential of SFRP2 methylation as a diagnostic and prognostic biomarker for CRC.
- To explore the therapeutic potential of SFRP2 in CRC.
Main Methods
- Examined SFRP2 expression and methylation status in blood, adipose, and colonic tissues from healthy individuals and CRC patients using qPCR, 450K DNA array, and DNA pyrosequencing.
- Validated findings in TCGA-COAD and TCGA-READ cohorts using publicly available scRNA-Seq data.
- Investigated the effect of recombinant human SFRP2 (rhSFRP2) on CRC cell proliferation, migration, and Wnt pathway gene expression.
Main Results
- SFRP2 promoter methylation in whole blood predicted cancer stage, lymph node invasion, and CRC recurrence (AUC > 0.65, p < 0.05).
- Observed global hypomethylation of SFRP2 in tumors compared to adjacent tissues, validated by hypermethylation and low expression in TCGA cohorts.
- Neoadjuvant-treated CRC patients had lower SFRP2 methylation; low methylation correlated with poor survival in untreated patients. rhSFRP2 inhibited CRC cell proliferation and migration.
Conclusions
- SFRP2 promoter methylation in blood is a promising prognostic candidate for CRC.
- SFRP2 methylation in tumors serves as a therapeutic prognostic indicator, valuable in clinical practice.
- SFRP2 presents potential as a therapeutic option, opening new clinical avenues.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
In most mammals, females have two X chromosomes (XX) while males have an X and a Y chromosome (XY). The X chromosome contains significantly more genes than the Y chromosome. Therefore, to prevent an excess of X chromosome-linked gene expression in females, one of the two X chromosomes is randomly silenced during early development....
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...